\
&
Contact us
This was 1 year ago
LocationSeville, Spain and online
ProgrammesAndalucia TRADE is hosting the International Forum on Dual-Use Technologies. This annual forum has contributed to fostering a dynamic ecosystem around dual-use technologies—those with both civilian and military applications—by bringing together SMEs, large corporations, research organizations, and universities to explore collaborative opportunities.
The 2024 edition focuses on the space industry, reflecting Seville's growing role in this sector. The city proudly hosts key organizations and initiatives related to space and innovation, highlighting its strategic importance in fostering industrial and technological development.
This forum is open to participants from research centres, SMEs, universities, large industries, incubators, start-ups, innovators, policymakers, institutions, investors, associations, and all professionals engaged in the space and defence sectors.
On Day 1 (29th October)
On Day 2 and Day 3 (30th, 31st October)
More information in B2B Meetings and on the website: https://dualuse2024.b2match.io/page-121
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.